Effect of single nucleotide polymorphism in thrombin-activatable fibrinolysis inhibitor on the risk of diabetic macrovascular disease. Issue 2 (March 2015)

• Record Type: Journal Article
• Authors: Zheng, Chenghong; Li, Xiaochao; Kong, Caixia; Ke, Shuhong; Peng, Cong; Cui, Tianpen; Gao, Mingsong; Zhou, Yang; Guo, Wei; Huang, Lianqi; Petersen, Robert B.; Huang, Kun
• Is Part Of: Blood coagulation and fibrinolysis. Volume 26:Issue 2(2015)
• Publication Date: 2015-03
• Subjects: antigen -- diabetic macrovascular disease -- thrombin-activatable fibrinolysis inhibitor polymorphism -- type 2 diabetes; Blood -- Coagulation -- Periodicals; Fibrinolysis -- Periodicals; Hemostasis -- Periodicals; Thrombosis -- Periodicals; Blood Coagulation -- Periodicals; Fibrinolysis -- Periodicals; Hemostasis -- Periodicals; Thrombosis -- Periodicals; 612.115
• DOI: 10.1097/MBC.0000000000000216
• Languages: English
• ISSNs: 0957-5235

Abstract

Abstract : Hypofibrinolysis is commonly found in patients with diabetes mellitus and is associated with the increased risk for many diabetic complications. An important inhibitor of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), participates in hypofibrinolysis in diabetes mellitus and may be involved in diabetic macrovascular disease. The present study was designed to determine whether TAFI polymorphisms (505G/A and 1040C/T) and TAFI levels are correlated with the development of type 2 diabetes mellitus (T2DM) and macrovascular diseases (MVDs). A total of 249 clinical samples were collected, including 102 healthy individuals (H group), 44 T2DM patients without MVD (T group) and 103 T2DM patients with MVD (M group). The 505G/A polymorphism was equally represented in the three groups. In contrast, analysis of the 1040C/T polymorphism revealed a statistically lower percentage of the T allele in the M group than in the H group ( P = 0.014). This difference was due to decreased T/T homozygotes in the M groups compared with the H group ( P = 0.029). The antigen TAFI level was 31.72 ± 13.64% in the H group, 62.56 ± 18.77% in the T group ( P < 0.05, compared with the H group) and 63.70 ± 15.76% in the M group ( P < 0.05, compared with the H group). As high plasma TAFI level is associated with the increasing risk of T2DM, it may thus serve as a potential marker for the diagnosis of T2DM.